Workplace Consulting & Worldwide Investigation
Genentech’s board rejected Roche’s initial friendly bid of $89 per share in July. Roche then shocked the company and Wall Street with a lowered $86.50-per-share bid on Jan. 30, aimed straight at shareholders. In January...
